IP Library Granted Patent US 11,780,924
Granted Patent B2
US 11,780,924 · App. 16/312,337 · Granted Oct 10, 2023

HLA binding vaccine moieties and uses thereof

Inventors: Gunnveig Grodeland (Oslo, NO); Bjarne Bogen (Oslo, NO); Agnete B. Fredriksen (Oslo, NO)
Assignees: UNIVERSITY OF OSLO; NYKODE THERAPEUTICS ASA
C07K16/2833A61K39/00A61K39/12A61K39/39C07K16/34C07K16/46C07K2317/53C07K2317/55C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,780,924
App. No.
16/312,337
Granted
Oct 10, 2023
Kind
B2
Abstract

The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.

Claims (12)

1. A nucleic acid comprising a sequence encoding an antibody, a scFv or a Fab fragment comprising light chain complementarity determining region (LCDR) 1 of SEQ ID NO:4; LCDR 2 of SEQ ID NO:5; and LCDR 3 of SEQ ID NO:6; and heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO:7; HCDR 2 of SEQ ID NO:8 and; HDCR 3 of SEQ ID NO:9.

2. The nucleic acid of claim 1 , further comprising a sequence encoding an antigen.

3. The nucleic acid of claim 1 , further comprising a sequence encoding at least two distinct antigens.

4. The nucleic acid of claim 2 , wherein antigen is derived from a pathogenic microorganism.

5. The nucleic acid of claim 4 , wherein said pathogenic microorganism is influenza virus or Ebola virus.

6. The nucleic acid of claim 2 , wherein said nucleic acid further comprises a linker sequence between said sequence encoding an antigen and said nucleic acid comprising a sequence encoding an antibody, a scFv or a Fab fragment.

7. The nucleic acid of claim 6 , wherein said linker comprises a dimerization unit comprising a hinge region from an immunoglobulin and an immunoglobulin constant region.

8. The nucleic acid of claim 7 , wherein said linker is a dimerization unit derived from a natural protein.

9. A pharmaceutical composition, comprising: the nucleic acid of claim 1 and a pharmaceutically acceptable carrier.

10. The composition of claim 9 , wherein said composition further comprises an adjuvant.

11. The nucleic acid of claim 1 , wherein the nucleic acid encodes the polypeptide of SEQ ID NO:1.

12. The nucleic acid of claim 4 , wherein said pathogenic microorganism is selected from the group consisting of orthomyxoviruses, paramyxoviruses, adenoviruses, rhinoviruses, coronaviruses, reoviruses, togaviruses, parvoviruses, poxviruses, enteroviruses, hepatitis viruses, herpesviruses, rotaviruses, Norwalk viruses, hantavirus, arenavirus, rhabdovirus, retroviruses, papovaviruses, polyomaviruses, picornaviruses, Dengue virus, Filoviruses, Hantavirus, Rift Valley virus, HHV-8, Human papillomavirus, Bovine leukemia virus, Influenza virus, Guanarito virus, Lassa virus, Measles virus, Rubella virus, Mumps virus, Chickenpox, Monkey pox, Epstein Bahr virus, Parvovirus B 19, Hantaan virus, Sin Nombre virus, Venezuelan equine encephalitis, Sabia virus, West Nile virus and Yellow Fever virus.

Assignments (4)
CHANGE OF NAME Recorded Aug 30, 2023
From: NYKODE THERAPEUTICS AS
To: NYKODE THERAPEUTICS ASA
Reel/Frame 064761/0125 →
CHANGE OF NAME Recorded Mar 29, 2022
From: VACCIBODY AS
To: NYKODE THERAPEUTICS AS
Reel/Frame 059426/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2019
From: GRODELAND, GUNNVEIG; BOGEN, BJARNE
To: UNIVERSITY OF OSLO
Reel/Frame 048656/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2019
From: FREDRIKSEN, AGNETE B.
To: VACCIBODY AS
Reel/Frame 048656/0473 →
Continuity (2)
Provisional Application 62352815 · Jun 21, 2016
Related Publication 20210403572A1 · Dec 30, 2021
Cited By (1)
US 12,358,989